# Tandem Diabetes Care Inc: financial statements, quarterly

TNDM · Nasdaq · CIK 1438133 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/tndm.md) · [Financials](/companies/tndm/financials.md) · [Filings](/companies/tndm/filings.md) · [Insiders](/companies/tndm/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/tndm/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [186](/filings/0001438133-24-000201.md) | [197](/filings/0001438133-25-000036.md) | [192](/filings/0001438133-25-000069.md) | [222](/filings/0001438133-25-000157.md) | [244](/filings/0001438133-25-000187.md) | [283](/filings/0001438133-26-000010.md) | [234](/filings/0001438133-26-000049.md) | [241](/filings/0001438133-26-000125.md) | [249](/filings/0001438133-25-000187.md) | [290](/filings/0001438133-26-000010.md) | [247](/filings/0001438133-26-000049.md) | [255](/filings/0001438133-26-000125.md) |
| Cost of revenue | $m | [95.9](/filings/0001438133-24-000201.md) | [104 d](/filings/0001438133-26-000010.md) | [97.0](/filings/0001438133-25-000069.md) | [109](/filings/0001438133-25-000157.md) | [119](/filings/0001438133-25-000187.md) | [125 d](/filings/0001438133-26-000010.md) | [116](/filings/0001438133-26-000049.md) | [115](/filings/0001438133-26-000125.md) | [115](/filings/0001438133-25-000187.md) | [123 d](/filings/0001438133-26-000010.md) | [110](/filings/0001438133-26-000049.md) | [110](/filings/0001438133-26-000125.md) |
| Gross profit | $m | [89.8](/filings/0001438133-24-000201.md) | [93.3](/filings/0001438133-25-000036.md) | [94.7](/filings/0001438133-25-000069.md) | [113](/filings/0001438133-25-000157.md) | [125](/filings/0001438133-25-000187.md) | [157](/filings/0001438133-26-000010.md) | [118](/filings/0001438133-26-000049.md) | [126](/filings/0001438133-26-000125.md) | [134](/filings/0001438133-25-000187.md) | [167](/filings/0001438133-26-000010.md) | [137](/filings/0001438133-26-000049.md) | [145](/filings/0001438133-26-000125.md) |
| Research and development | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Selling, general and administrative | $m | [79.3](/filings/0001438133-24-000201.md) | [85.8 d](/filings/0001438133-26-000010.md) | [90.1](/filings/0001438133-25-000069.md) | [94.2](/filings/0001438133-25-000157.md) | [99.6](/filings/0001438133-25-000187.md) | [106 d](/filings/0001438133-26-000010.md) | [114](/filings/0001438133-26-000049.md) | [110](/filings/0001438133-26-000125.md) | [108](/filings/0001438133-25-000187.md) | [113 d](/filings/0001438133-26-000010.md) | [108](/filings/0001438133-26-000049.md) | [112](/filings/0001438133-26-000125.md) |
| Operating income | $m | [(31.5)](/filings/0001438133-24-000201.md) | [(35.1)](/filings/0001438133-25-000036.md) | [(41.7)](/filings/0001438133-25-000069.md) | [(30.8)](/filings/0001438133-25-000157.md) | [(26.1)](/filings/0001438133-25-000187.md) | [(0.6)](/filings/0001438133-26-000010.md) | [(121)](/filings/0001438133-26-000049.md) | [(51.8)](/filings/0001438133-26-000125.md) | [(22.9)](/filings/0001438133-25-000187.md) | [8.3](/filings/0001438133-26-000010.md) | [(17.4)](/filings/0001438133-26-000049.md) | [(13.8)](/filings/0001438133-26-000125.md) |
| Interest expense | $m | [4.8](/filings/0001438133-24-000201.md) | [1.8 d](/filings/0001438133-26-000010.md) | [1.9](/filings/0001438133-25-000069.md) | [1.8](/filings/0001438133-25-000157.md) | [1.9](/filings/0001438133-25-000187.md) | [1.9 d](/filings/0001438133-26-000010.md) | [1.9](/filings/0001438133-26-000049.md) | [1.9](/filings/0001438133-26-000125.md) | [2.1](/filings/0001438133-25-000187.md) | [2.1 d](/filings/0001438133-26-000010.md) | [2.2](/filings/0001438133-26-000049.md) | [2.5](/filings/0001438133-26-000125.md) |
| Income tax | $m | [2.2](/filings/0001438133-24-000201.md) | [(1.3) d](/filings/0001438133-26-000010.md) | [3.2](/filings/0001438133-25-000069.md) | [1.1](/filings/0001438133-25-000157.md) | [0.6](/filings/0001438133-25-000187.md) | [(0.7) d](/filings/0001438133-26-000010.md) | [8.5](/filings/0001438133-26-000049.md) | [(5.3)](/filings/0001438133-26-000125.md) | [(4.0)](/filings/0001438133-25-000187.md) | [5.3 d](/filings/0001438133-26-000010.md) | [0.5](/filings/0001438133-26-000049.md) | [0.5](/filings/0001438133-26-000125.md) |
| Net income | $m | [(33.0)](/filings/0001438133-24-000201.md) | [(30.0)](/filings/0001438133-25-000036.md) | [(42.7)](/filings/0001438133-25-000069.md) | [(30.8)](/filings/0001438133-25-000157.md) | [(23.3)](/filings/0001438133-25-000187.md) | [0.8](/filings/0001438133-26-000010.md) | [(131)](/filings/0001438133-26-000049.md) | [(52.4)](/filings/0001438133-26-000125.md) | [(21.2)](/filings/0001438133-25-000187.md) | [(0.6)](/filings/0001438133-26-000010.md) | [(20.4)](/filings/0001438133-26-000049.md) | [(21.2)](/filings/0001438133-26-000125.md) |
| Diluted EPS | $ per share | [(0.51)](/filings/0001438133-24-000201.md) | [(0.46)](/filings/0001438133-25-000036.md) | [(0.65)](/filings/0001438133-25-000069.md) | [(0.47)](/filings/0001438133-25-000157.md) | [(0.35)](/filings/0001438133-25-000187.md) | [0.01](/filings/0001438133-26-000010.md) | [(1.97)](/filings/0001438133-26-000049.md) | [(0.78)](/filings/0001438133-26-000125.md) | [(0.31)](/filings/0001438133-25-000187.md) | [(0.01)](/filings/0001438133-26-000010.md) | [(0.30)](/filings/0001438133-26-000049.md) | [(0.31)](/filings/0001438133-26-000125.md) |
| Basic EPS | $ per share | [(0.51)](/filings/0001438133-24-000201.md) | [(0.46)](/filings/0001438133-25-000036.md) | [(0.65)](/filings/0001438133-25-000069.md) | [(0.47)](/filings/0001438133-25-000157.md) | [(0.35)](/filings/0001438133-25-000187.md) | [0.01](/filings/0001438133-26-000010.md) | [(1.97)](/filings/0001438133-26-000049.md) | [(0.78)](/filings/0001438133-26-000125.md) | [(0.31)](/filings/0001438133-25-000187.md) | [(0.01)](/filings/0001438133-26-000010.md) | [(0.30)](/filings/0001438133-26-000049.md) | [(0.31)](/filings/0001438133-26-000125.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: not reported
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [79.6](/filings/0001438133-23-000207.md) | [58.9](/filings/0001438133-25-000036.md) | [59.0](/filings/0001438133-24-000086.md) | [47.7](/filings/0001438133-24-000177.md) | [49.0](/filings/0001438133-24-000201.md) | [69.2](/filings/0001438133-26-000010.md) | [53.6](/filings/0001438133-25-000069.md) | [64.1](/filings/0001438133-25-000157.md) | [91.9](/filings/0001438133-25-000187.md) | [90.6](/filings/0001438133-26-000125.md) | [179](/filings/0001438133-26-000049.md) | [62.8](/filings/0001438133-26-000125.md) |
| Current assets | $m | [758](/filings/0001438133-23-000207.md) | [748](/filings/0001438133-25-000036.md) | [735](/filings/0001438133-24-000086.md) | [733](/filings/0001438133-24-000177.md) | [753](/filings/0001438133-24-000201.md) | [724](/filings/0001438133-26-000010.md) | [663](/filings/0001438133-25-000069.md) | [615](/filings/0001438133-25-000157.md) | [617](/filings/0001438133-25-000187.md) | [618](/filings/0001438133-26-000125.md) | [887](/filings/0001438133-26-000049.md) | [805](/filings/0001438133-26-000125.md) |
| Total assets | $m | [940](/filings/0001438133-23-000207.md) | [953](/filings/0001438133-25-000036.md) | [941](/filings/0001438133-24-000086.md) | [938](/filings/0001438133-24-000177.md) | [958](/filings/0001438133-24-000201.md) | [968](/filings/0001438133-26-000010.md) | [922](/filings/0001438133-25-000069.md) | [876](/filings/0001438133-25-000157.md) | [875](/filings/0001438133-25-000187.md) | [881](/filings/0001438133-26-000125.md) | [1,153](/filings/0001438133-26-000049.md) | [1,154](/filings/0001438133-26-000125.md) |
| Current liabilities | $m | [187](/filings/0001438133-23-000207.md) | [195](/filings/0001438133-25-000036.md) | [193](/filings/0001438133-24-000086.md) | [241](/filings/0001438133-24-000177.md) | [259](/filings/0001438133-24-000201.md) | [247](/filings/0001438133-26-000010.md) | [288](/filings/0001438133-25-000069.md) | [252](/filings/0001438133-25-000157.md) | [253](/filings/0001438133-25-000187.md) | [243](/filings/0001438133-26-000125.md) | [248](/filings/0001438133-26-000049.md) | [253](/filings/0001438133-26-000125.md) |
| Total liabilities | $m | [626](/filings/0001438133-23-000207.md) | [639](/filings/0001438133-25-000036.md) | [698](/filings/0001438133-24-000086.md) | [704](/filings/0001438133-24-000177.md) | [720](/filings/0001438133-24-000201.md) | [705](/filings/0001438133-26-000010.md) | [767](/filings/0001438133-25-000069.md) | [742](/filings/0001438133-25-000157.md) | [742](/filings/0001438133-25-000187.md) | [726](/filings/0001438133-26-000125.md) | [1,021](/filings/0001438133-26-000049.md) | [1,024](/filings/0001438133-26-000125.md) |
| Long-term debt | $m | not reported | [285](/filings/0001438133-25-000036.md) | not reported | [307](/filings/0001438133-24-000177.md) | [308](/filings/0001438133-24-000201.md) | [308](/filings/0001438133-26-000010.md) | [309](/filings/0001438133-25-000069.md) | [309](/filings/0001438133-25-000157.md) | [310](/filings/0001438133-25-000187.md) | [310](/filings/0001438133-26-000125.md) | [602](/filings/0001438133-26-000049.md) | [603](/filings/0001438133-26-000125.md) |
| Current portion of debt | $m | not reported | [0.0](/filings/0001438133-25-000036.md) | not reported | [40.5](/filings/0001438133-24-000177.md) | [40.6](/filings/0001438133-24-000201.md) | [40.7](/filings/0001438133-25-000036.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [314](/filings/0001438133-24-000201.md) | [314](/filings/0001438133-26-000010.md) | [243](/filings/0001438133-25-000157.md) | [234](/filings/0001438133-25-000187.md) | [238](/filings/0001438133-25-000187.md) | [263](/filings/0001438133-26-000125.md) | [155](/filings/0001438133-26-000125.md) | [133](/filings/0001438133-26-000125.md) | [133](/filings/0001438133-25-000187.md) | [155](/filings/0001438133-26-000125.md) | [132](/filings/0001438133-26-000125.md) | [130](/filings/0001438133-26-000125.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [0.1 d](/filings/0001438133-24-000201.md) | [(7.2) d](/filings/0001438133-26-000010.md) | [(8.0)](/filings/0001438133-25-000069.md) | [(5.3) d](/filings/0001438133-25-000157.md) | [26.8 d](/filings/0001438133-25-000187.md) | [10.7 d](/filings/0001438133-26-000010.md) | [(18.3)](/filings/0001438133-26-000049.md) | [(9.5) d](/filings/0001438133-26-000125.md) | [8.3 d](/filings/0001438133-25-000187.md) | [9.8 d](/filings/0001438133-26-000010.md) | [11.1](/filings/0001438133-26-000049.md) | [(34.6) d](/filings/0001438133-26-000125.md) |
| Capital expenditure | $m | [5.4 d](/filings/0001438133-24-000201.md) | [5.2 d](/filings/0001438133-26-000010.md) | [4.5](/filings/0001438133-25-000069.md) | [6.5 d](/filings/0001438133-25-000157.md) | [5.2 d](/filings/0001438133-25-000187.md) | [3.1 d](/filings/0001438133-26-000010.md) | [3.0](/filings/0001438133-26-000049.md) | [6.2 d](/filings/0001438133-26-000125.md) | [4.1 d](/filings/0001438133-25-000187.md) | [6.7 d](/filings/0001438133-26-000010.md) | [6.3](/filings/0001438133-26-000049.md) | [4.1 d](/filings/0001438133-26-000125.md) |
| Share repurchases | $m | not reported | not reported | [30.0](/filings/0001438133-25-000069.md) | [0.0 d](/filings/0001438133-25-000157.md) | [0.0 d](/filings/0001438133-25-000187.md) | [0.0 d](/filings/0001438133-26-000010.md) | [0.0](/filings/0001438133-25-000069.md) | [0.0 d](/filings/0001438133-25-000157.md) | [0.0 d](/filings/0001438133-25-000187.md) | [0.0 d](/filings/0001438133-26-000010.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [65.1](/filings/0001438133-24-000201.md) | [65.4](/filings/0001438133-25-000036.md) | [65.3](/filings/0001438133-25-000069.md) | [65.0](/filings/0001438133-25-000157.md) | [65.5](/filings/0001438133-25-000187.md) | [66.2](/filings/0001438133-26-000010.md) | [66.4](/filings/0001438133-26-000049.md) | [67.1](/filings/0001438133-26-000125.md) | [67.7](/filings/0001438133-25-000187.md) | [68.0](/filings/0001438133-26-000010.md) | [68.4](/filings/0001438133-26-000049.md) | [69.0](/filings/0001438133-26-000125.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 69,578,707 at 2026-08-03, from the cover of the [10-Q filed 2026-08-06](/filings/0001438133-26-000125.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:40 ET. No prices; not investment advice.